Ratings Medical Properties Trust, Inc.

Equities

MPW

US58463J3041

Market Closed - Nyse 04:00:02 2024-03-28 pm EDT 5-day change 1st Jan Change
4.7 USD -0.42% Intraday chart for Medical Properties Trust, Inc. +10.59% -4.28%

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.
  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • The equity is one of the most attractive in the market with regard to earnings multiple-based valuation.
  • The company's share price in relation to its net book value makes it look relatively cheap.
  • This company will be of major interest to investors in search of a high dividend stock.

Weaknesses

  • The company's earnings growth outlook lacks momentum and is a weakness.
  • One of the major weak points of the company is its financial situation.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
  • Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Specialized REITs

1st Jan change Capi. Investor Rating ESG Refinitiv
-3.05% 2.83B
C
+3.68% 52.79B
A-
-12.22% 17.56B
A-
-5.40% 12.99B
A
-19.09% 5.31B
B-
+3.90% 3.37B
C+
+9.25% 3.27B
C-
-10.60% 2.89B
B+
+11.64% 2.68B
C-
-15.48% 2.35B
A-
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes